Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Scott Kinlay, Ph.D., M.B.,B.S.

Concepts

This page shows the publications Scott Kinlay has written about Cholesterol, LDL.
Connection Strength

0.585
  1. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol. 2007 May 22; 49(20):2003-9.
    View in: PubMed
    Score: 0.177
  2. Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points. Curr Opin Lipidol. 1996 Dec; 7(6):389-97.
    View in: PubMed
    Score: 0.086
  3. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96.
    View in: PubMed
    Score: 0.051
  4. Vascular form and function: two mechanisms for cardiovascular prevention. Eur Heart J. 2008 Jul; 29(14):1711-3.
    View in: PubMed
    Score: 0.048
  5. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7.
    View in: PubMed
    Score: 0.046
  6. Vascular basis for the treatment of myocardial ischemia study: trial design and baseline characteristics. Am Heart J. 2004 May; 147(5):875-82.
    View in: PubMed
    Score: 0.036
  7. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6.
    View in: PubMed
    Score: 0.034
  8. Effects of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol. 2003 Feb 20; 91(4A):9B-13B.
    View in: PubMed
    Score: 0.033
  9. Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol. 2002 May 15; 89(10):1205-7.
    View in: PubMed
    Score: 0.031
  10. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997 Jan 07; 95(1):5-7.
    View in: PubMed
    Score: 0.022
  11. Reproducibility of coronary lumen, plaque, and vessel wall reconstruction and of endothelial shear stress measurements in vivo in humans. Catheter Cardiovasc Interv. 2003 Sep; 60(1):67-78.
    View in: PubMed
    Score: 0.009
  12. Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. Curr Atheroscler Rep. 2000 Jul; 2(4):321-6.
    View in: PubMed
    Score: 0.007
  13. Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. Am J Cardiol. 1997 Mar 06; 79(5A):17-23.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.